Literature DB >> 9324080

Safety and efficacy of strength training in patients with sporadic inclusion body myositis.

S A Spector1, J T Lemmer, B M Koffman, T A Fleisher, I M Feuerstein, B F Hurley, M C Dalakas.   

Abstract

We studied the effects of a 12-week progressive resistance strength training program in weakened muscles of 5 patients with sporadic inclusion body myositis (IBM). Strength was evaluated with Medical Research Council (MRC) scale ratings and quantitative isometric and dynamic tests. Changes in serum creatine kinase (CK), lymphocyte subpopulations, muscle size (determined by magnetic resonance imaging), and histology in repeated muscle biopsies were examined before and after training. After 12 weeks, the values of repetition maximum improved in the least weakened muscles, 25-120% from baseline. This dynamic effect was not captured by MRC or isometric muscle strength measurements. Serum CK, B cells, T-cell subsets, and NK cells remained unchanged. Repeat muscle biopsies did not reveal changes in the number and degree of degenerating fibers or inflammation. The size of the trained muscles did not change. We conclude that a supervised progressive resistance training program in IBM patients can lead to gains in dynamic strength of the least weak muscles without causing muscle fatigue and muscle injury or serological, histological, and immunological abnormalities. Even though the functional significance of these gains is unclear, this treatment modality is a safe and perhaps overlooked means of rehabilitation of IBM patients.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9324080     DOI: 10.1002/(sici)1097-4598(199710)20:10<1242::aid-mus6>3.0.co;2-c

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  28 in total

1.  Therapeutic advances and future prospects in immune-mediated inflammatory myopathies.

Authors:  Marinos C Dalakas
Journal:  Ther Adv Neurol Disord       Date:  2008-11       Impact factor: 6.570

Review 2.  The relevance of applying exercise training principles when designing therapeutic interventions for patients with inflammatory myopathies: a systematic review.

Authors:  Pierrette Baschung Pfister; Eling D de Bruin; Bernadette C Tobler-Ammann; Britta Maurer; Ruud H Knols
Journal:  Rheumatol Int       Date:  2015-08-14       Impact factor: 2.631

Review 3.  Immunotherapy of myositis: issues, concerns and future prospects.

Authors:  Marinos C Dalakas
Journal:  Nat Rev Rheumatol       Date:  2010-02-02       Impact factor: 20.543

Review 4.  Update on treatment of inclusion body myositis.

Authors:  Maren Breithaupt; Jens Schmidt
Journal:  Curr Rheumatol Rep       Date:  2013-05       Impact factor: 4.592

Review 5.  Inclusion Body Myositis: Update on Pathogenesis and Treatment.

Authors:  Elie Naddaf; Richard J Barohn; Mazen M Dimachkie
Journal:  Neurotherapeutics       Date:  2018-10       Impact factor: 7.620

Review 6.  The benefits and limitations of a physical training program in patients with inflammatory myositis.

Authors:  M Lawson Mahowald
Journal:  Curr Rheumatol Rep       Date:  2001-08       Impact factor: 4.592

7.  Vascular occlusion training for inclusion body myositis: a novel therapeutic approach.

Authors:  Bruno Gualano; Carlos Ugrinowitsch; Manoel Neves; Fernanda R Lima; Ana Lúcia S Pinto; Gilberto Laurentino; Valmor A A Tricoli; Antonio H Lancha; Hamilton Roschel
Journal:  J Vis Exp       Date:  2010-06-05       Impact factor: 1.355

Review 8.  Exercise: an important component of treatment in the idiopathic inflammatory myopathies.

Authors:  Helene Alexanderson
Journal:  Curr Rheumatol Rep       Date:  2005-04       Impact factor: 4.592

Review 9.  Strength training and aerobic exercise training for muscle disease.

Authors:  Nicoline Bm Voet; Elly L van der Kooi; Baziel Gm van Engelen; Alexander Ch Geurts
Journal:  Cochrane Database Syst Rev       Date:  2019-12-06

10.  How citation distortions create unfounded authority: analysis of a citation network.

Authors:  Steven A Greenberg
Journal:  BMJ       Date:  2009-07-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.